News & Updates

TACE + apatinib: A potential new strategy for intermediate/advanced HCC?

ALXN1840 generates rapid, sustained copper mobilization in Wilson disease

In individuals with Wilson disease (WD), a rare disease of copper metabolism, ALXN1840 led to significantly greater copper mobilization compared with standard of care (SoC), findings from a rater-blinded phase III study have shown.

Maralixibat improves pruritus across all PFIC types

Treatment with maralixibat significantly reduced the severity of pruritus in children with progressive familial intrahepatic cholestasis (PFIC) in the MARCH-PFIC* study presented at The Liver Meeting 2022.

Digital pathology with AI offers new insights into fibrosis regression in NASH

Second harmonic generation/two-photon excitation fluorescence (SHG/TPEF) microscopy with artificial intelligence (AI) analyses reveals novel facets of treatment-induced fibrosis regression in nonalcoholic steatohepatitis (NASH), which are not normally captured by existing staging systems, reports a study.

Odevixibat improves pruritus, reduces bile acids in children with ALGS

Treatment with odevixibat, a potent, selective IBAT* inhibitor, significantly improved pruritus and reduced serum bile acid levels in children with Alagille syndrome (ALGS), according to the ASSERT** trial presented at The Liver Meeting 2022.

Resmetirom safe, effective in improving NASH fibrosis markers

Treatment with the selective THR-β* agonist resmetirom for 52 weeks was well-tolerated and effective in reducing markers of NASH** fibrosis in a well-compensated Child-Pugh (CP)-A NASH population, a phase III trial has shown.

High-intensity focused ultrasound safe, effective for cirrhotic secondary hypersplenism

High-intensity focused ultrasound (HIFU) appears to be a safe, effective, and minimally invasive treatment option for patients with cirrhotic secondary hypersplenism, a recent study has found.

Midodrine a novel option for PICD prevention in ACLF

Oral midodrine may be a good alternative to intravenous albumin for preventing paracentesis-induced circulatory dysfunction (PICD) in patients with acute-on-chronic liver failure (ACLF) undergoing modest-volume paracentesis for ascites, suggests a new study.